Clinical Trial in Chinese Healthy Volunteers of GB222

PHASE1UnknownINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

August 31, 2020

Study Completion Date

November 30, 2020

Conditions
Non-small Cell Lung Cancer
Interventions
BIOLOGICAL

GB222

Recombinant humanized antivascular endothelial growth factor monoclonal antibody injection Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is \> 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.

BIOLOGICAL

Bevacizumab

Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is \> 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.

Trial Locations (1)

100034

RECRUITING

People's Hospital of Peking University, Beijing

Sponsors
All Listed Sponsors
lead

Genor Biopharma Co., Ltd.

INDUSTRY